- Home
- CRML vs OMER Comparison
CRML vs OMER Comparison
Compare CRML & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- OMER
- Stock Information
- Founded
- CRML N/A
- OMER 1994
- Country
- CRML United States
- OMER United States
- Employees
- CRML N/A
- OMER N/A
- Industry
- CRML
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CRML
- OMER Health Care
- Exchange
- CRML NYSE
- OMER Nasdaq
- Market Cap
- CRML 634.1M
- OMER 667.0M
- IPO Year
- CRML N/A
- OMER 2009
- Fundamental
- Price
- CRML $6.74
- OMER $7.66
- Analyst Decision
- CRML
- OMER Buy
- Analyst Count
- CRML 0
- OMER 3
- Target Price
- CRML N/A
- OMER $9.00
- AVG Volume (30 Days)
- CRML 20.7K
- OMER 1.0M
- Earning Date
- CRML 02-01-2025
- OMER 11-13-2024
- Dividend Yield
- CRML N/A
- OMER N/A
- EPS Growth
- CRML N/A
- OMER N/A
- EPS
- CRML N/A
- OMER N/A
- Revenue
- CRML $117,660.00
- OMER N/A
- Revenue This Year
- CRML N/A
- OMER N/A
- Revenue Next Year
- CRML N/A
- OMER N/A
- P/E Ratio
- CRML N/A
- OMER N/A
- Revenue Growth
- CRML 5.79
- OMER N/A
- 52 Week Low
- CRML $5.32
- OMER $2.61
- 52 Week High
- CRML $22.50
- OMER $12.65
- Technical
- Relative Strength Index (RSI)
- CRML 47.79
- OMER 44.76
- Support Level
- CRML $6.25
- OMER $7.33
- Resistance Level
- CRML $6.86
- OMER $8.10
- Average True Range (ATR)
- CRML 0.75
- OMER 1.01
- MACD
- CRML -0.08
- OMER -0.62
- Stochastic Oscillator
- CRML 19.68
- OMER 8.08
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.